Avanza Fonder AB Invests $4.96 Million in Cencora, Inc. (NYSE:COR)

Avanza Fonder AB purchased a new position in Cencora, Inc. (NYSE:COR) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 22,076 shares of the company’s stock, valued at approximately $4,960,000.

A number of other institutional investors and hedge funds have also modified their holdings of COR. Concord Wealth Partners purchased a new position in Cencora during the third quarter worth approximately $30,000. SYSTM Wealth Solutions LLC purchased a new position in shares of Cencora during the second quarter worth $36,000. Ashton Thomas Securities LLC acquired a new position in Cencora in the 3rd quarter valued at about $41,000. Fairscale Capital LLC acquired a new position in shares of Cencora in the second quarter valued at approximately $54,000. Finally, Modus Advisors LLC purchased a new stake in shares of Cencora during the fourth quarter worth $54,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

COR has been the subject of a number of research analyst reports. Robert W. Baird upped their target price on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Barclays upped their price objective on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. UBS Group increased their target price on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, November 7th. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Finally, Wells Fargo & Company cut their price target on Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a research note on Friday, December 13th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, Cencora has a consensus rating of “Moderate Buy” and a consensus price target of $275.60.

Insiders Place Their Bets

In other news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Chairman Steven H. Collis sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the sale, the chairman now owns 326,557 shares of the company’s stock, valued at approximately $79,670,111.29. The trade was a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 94,696 shares of company stock valued at $22,862,734. Insiders own 15.80% of the company’s stock.

Cencora Trading Down 0.6 %

Shares of COR opened at $239.41 on Friday. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $253.27. The company has a market capitalization of $46.27 billion, a PE ratio of 31.88, a price-to-earnings-growth ratio of 1.48 and a beta of 0.49. The stock has a fifty day moving average of $237.65 and a two-hundred day moving average of $233.72. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, November 15th. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.92%. Cencora’s dividend payout ratio is 29.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.